



American Red Cross

Pooled Cryoprecipitate Any-Type Ordering



The American Red Cross offers Pooled Cryoprecipitate, enabling hospitals to effectively treat massive hemorrhage and support trauma resuscitation.

Enabling product sustainability through Any-Type Inventory Management

The United States has experienced growing demand for Pooled Cryoprecipitate in recent years, an increase not seen with other blood products. The enduring increase in product demand, distribution and transfusion, requires a reexamination of existing ordering protocols to ensure hospital needs can be met.

Contemporary research supports that type-specific Pooled Cryoprecipitate products are medically unnecessary for most adult patients receiving Cryoprecipitate transfusions. Additionally, when used in comparatively small volume dosing consistent with most transfusion practices, Pooled Cryoprecipitate allows for any-type transfusion—facilitating rapid access and reducing waste associated with stocking type-specific products. Residual type-specific Pooled Cryoprecipitate orders increasingly strain the Red Cross inventory, often leading to the inability to fulfill orders in the requested timeframe.

Pooled Cryoprecipitate risk analysis supports current Transfusion Medicine standard statements on safety of transfusing Cryoprecipitate to adults without need for ABO matching.

- The probability of a 10-unit pool of single ABO type Cryoprecipitate yielding an anti-A or anti-B titer > 1:100 is predicted to be less than 1 in 3 million.²
- In a post-hoc analysis of data from the FIBRES trial, there was no significant increase in hemolytic events or transfusion requirement in patients who received ABO-incompatible cryoprecipitate.³

Contact your local Red Cross Representative to learn more about how following any-type Pooled Cryoprecipitate utilization guidance can increase product inventory optimization and maximize order fulfillment rates.

Product Description	Product Code	Ordering Information
<ul style="list-style-type: none"> ▪ Pooled Cryoprecipitate from PF24 ▪ 5-donor pools with same ABO ▪ 100 mL average volume ▪ 3,000 mg average fibrinogen content at thaw ▪ 12-months frozen shelf-life ▪ 6-hours post-thaw shelf life 	<p>E3587V00</p> <ul style="list-style-type: none"> ▪ Pooled Cryoprecipitate AHF 	<ul style="list-style-type: none"> ▪ Any-Type Order Fulfillment ▪ Scheduled orders recommended ▪ Ad Hoc ordering available ▪ No returns

References:

1. Hadjesfandiari N, Levin E, Serrano K, Yi QL, Devine DV. Risk analysis of transfusion of cryoprecipitate without consideration of ABO group. *Transfusion*. 2021 Jan;61(1):29-34. doi: 10.1111/trf.16125. Epub 2020 Oct 10. PMID: 33037661.
2. Berseus O, Boman K, Nessen SC, Westerberg LA. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. *Transfusion*. 2013;53(suppl 1): 114S-123S.
3. Raycraft T, Bartoszko J, Karkouti K, Callum J, Lin Y. Practice patterns of ABO-matching for cryoprecipitate and patient outcomes after ABO-compatible versus incompatible cryoprecipitate. *Vox Sang*. 2022 Sep;117(9):1105-1111. doi: 10.1111/vox.13330. Epub 2022 Jul 6. PMID: 35791670.
4. Jones JM, Sapiano MRP, Savinkina AA, et al. Slowing decline in blood collection and transfusion in the United States - 2017. *Transfusion*. 2020; 60: S1-S9.
5. Free, RJ, Sapiano, MRP, Chavez Ortiz, JL, Stewart, P, Berger, J, Basavaraju, SV. Continued stabilization of blood collections and transfusions in the United States: Findings from the 2021 National Blood Collection and Utilization Survey. *Transfusion*. 2023; 63(S4): S8-S18. <https://doi.org/10.1111/trf.17360>